Grifols shared its Q3 2026 results, showing an 8.4% rise in sales and a 27.9% jump in profit.

Nov 2, 2026, 12:08 PM ETResultsRead the original at tradingview.com

Good for GRFS

Grifols grew revenue 8.4% and profit 27.9%, added €110 million to nine-month free cash flow, and lowered its leverage ratio to 3.98x. Immunoglobulin growth and its unchanged 2026 forecast outweigh continued pressure from China's albumin market.

GRFS · Grifols, S.A.

AI read · Good for GRFS

The AI's read

Improved cash generation and a lower leverage ratio leave Grifols in a stronger position. Immunoglobulin growth and its unchanged 2026 forecast support that reading. China’s albumin market still weighs on performance, but the reported gains across sales, profit, and cash flow outweigh that pressure.

Get alerts for GRFS

Follow Grifols, S.A. (GRFS) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for GRFS

Free on the App Store and Google Play, or on the web.